KRAS and colorectal carcinoma: Verissimo and colleagues tested KRAS pathway inhibitors and combinations of drugs on normal colon organoids and CRC PDTOs and demonstrated that only organoids harbouring KRAS mutations were resistant to the treatments (Verissimo et al, 2016).